Working… Menu
Trial record 27 of 811 for:    Psoriasis 4

A Proof of Concept Study Comparing Three Doses of an Oral Solution of LEO 22811 With a Placebo Oral Solution for the Treatment of Psoriasis Vulgaris

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01116895
Recruitment Status : Completed
First Posted : May 5, 2010
Results First Posted : October 3, 2018
Last Update Posted : December 20, 2018
Information provided by (Responsible Party):
LEO Pharma

Brief Summary:
An international, multi-centre, prospective, randomised, double-blind, 4-arm, placebo controlled, parallel group study with 12 weeks once daily oral treatment in subjects with psoriasis vulgaris.

Condition or disease Intervention/treatment Phase
Psoriasis Vulgaris Drug: LEO 22811 Drug: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 63 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: An International, Multi-centre, Prospective, Randomised, Double-blind, 4-arm, Placebo Controlled, Parallel Group Study With 12 Weeks Once Daily Oral Treatment in Subjects With Psoriasis Vulgaris
Study Start Date : May 2010
Actual Primary Completion Date : March 2011
Actual Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Active Comparator: LEO 22811 0.5 mg
LEO 22811 0.5 mg: Oral solution
Drug: LEO 22811
Oral solution

Active Comparator: LEO 22811 1.5 mg
LEO 22811 1.5 mg: Oral solution
Drug: LEO 22811
Oral solution

Active Comparator: LEO 22811 3.0 mg
LEO 22811 3.0 mg: Oral solution
Drug: LEO 22811
Oral solution

Placebo Comparator: Placebo
Placebo: Oral solution
Drug: Placebo

Primary Outcome Measures :
  1. Percentage Change in Psoriasis Area and Severity Index (PASI) [ Time Frame: Baseline (Day 0) to end of treatment (Day 84) ]

    The investigator made assessments of the extent and severity of clinical signs of the participant's psoriasis on specific areas of the body in terms of three clinical signs: redness, thickness and scaliness.

    The extent of psoriatic involvement was recorded for each of four areas; head, arms, trunk and legs using the following scale:

    0. = no involvement

    1. = <10%
    2. = 10-29%
    3. = 30-49%
    4. = 50-69%
    5. = 70-89%
    6. = 90-100%

    For each clinical sign a single score (0, 1, 2, 3 or 4) reflecting the average severity of all psoriatic lesions on the given body region was determined.

    PASI was calculated based on the investigator's assessment of the disease locally (head, trunk, arm, legs) using the following formula:

    Head: 0.1 (R + T + S)E = W Arms: 0.2 (R + T + S)E = X Trunk: 0.3 (R + T + S)E = Y Legs: 0.4 (R + T + S)E = Z R = score for redness; T = score for thickness, S = score for scaliness; E = score for extent The sum of W+X+Y+Z gives the total PASI that ranges from 0 to 72.

Secondary Outcome Measures :
  1. Participants With at Least 75% Reduction in PASI (PASI 75) [ Time Frame: From baseline (Day 0) to end of treatment (Day 84) ]
  2. Participants With at Least 50% Reduction in PASI (PASI 50) [ Time Frame: From baseline (Day 0) to end of treatment (Day 84) ]
  3. Participants With "Controlled Disease" According to the Investigators' Global Assessment (IGA) [ Time Frame: At end of treatment (Day 84) ]
    At Visits 1 to 8 the investigator made a global assessment of the disease severity (IGA) using a 6-point scale (clear, almost clear, mild, moderate, severe, very severe). This assessment represents average lesion severity on head, trunk, arm and legs. The assessment was based on the condition of the disease at the time of evaluation and not in relation to the condition at a previous visit. Participants classified as clear or almost clear according to IGA was considered to have "controlled disease".

  4. Participants With Satisfactory Response According to IGA [ Time Frame: At end of treatment (Day 84) ]
    "Satisfactory response" was defined as participants classified as "Clear" or "Almost Clear" or "Mild" according to the IGA.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Following verbal and written information about the trial the subject must provide signed and dated informed consent before any study related activity is carried out, including activities relating to the washout period.
  • Clinical diagnosis of psoriasis vulgaris, for at least 6 months prior to randomisation, and currently covering at least 10% of the body surface area (BSA)
  • Candidates for systemic anti-psoriatic treatment
  • Psoriasis Area and Severity Index (PASI) ≥10
  • Disease severity of moderate, severe or very severe according to the Investigators' Global Assessment of disease severity (IGA)
  • Aged 18 years or above
  • Any race or ethnicity
  • Males, surgically sterile females (bilateral tubal ligation, bilateral oophorectomy or hysterectomy) or post menopausal females (at least 1 year since last menses)
  • Attending hospital outpatient clinic or the private practice of a dermatologist

Exclusion Criteria:

  • Systemic treatment with biological therapies whether marketed or not with a possible effect on psoriasis vulgaris within the following time periods prior to randomisation:

    • Etanercept - 4 weeks
    • Adalimumab, alefacept, infliximab - 2 months
    • Ustekinumab - 4 months
  • Systemic treatment with all other therapies (other than biologics) with a possible effect on psoriasis vulgaris (e.g.corticosteroids, retinoids, immunosuppressants, methotrexate, cyclosporin or fumaric acid) within 4 weeks prior to randomisation
  • PUVA therapy within 4 weeks prior to randomisation
  • UVB therapy within 2 weeks prior to randomisation
  • Any topical treatment (except for emollients/ medicated shampoo) within 2 weeks prior to randomisation
  • Initiation of, or changes to concomitant medication that could affect psoriasis vulgaris (e.g. beta-blockers, anti-malaria drugs, lithium) 2 weeks prior to randomisation and during the study
  • Current diagnosis with erythrodermic, exfoliative or pustular psoriasis
  • Other current skin conditions that may confound the evaluation of psoriasis vulgaris as judged by the Investigator
  • Generally in good health and does not have any clinically significant cardiac, endocrinologic, pulmonary, neurologic, psychiatric, hepatic, renal, haematologic, or gastrointestinal disease, immunologic insufficiency, or other major diseases or current condition which, in the opinion of the Investigator, would put the subject at risk by participating in the study
  • Current active tuberculosis or latent tuberculosis
  • Planned exposure to the sun during the study that may affect psoriasis vulgaris
  • Known malignancy or history of malignancy (other than cervical carcinoma in situ, basal cell or squamous cell carcinoma) within the 5 year period prior to randomisation
  • Live vaccination within the 4 weeks prior to randomisation
  • Males who do not agree to use adequate contraception during the study (including follow-up) to ensure their partner does not become pregnant
  • Known or suspected hypersensitivity to component(s) of the investigational product
  • Current participation in any other interventional trial
  • Treatment with any non-marketed drug substance (i.e. an agent which has not yet been made available for clinical use following registration) within 4 weeks or 5 half-lives (whichever is longer) prior to randomisation
  • Previously randomised in this study
  • Known or, in the opinion of the Investigator, is unlikely to comply with the Clinical Study Protocol (e.g., alcohol abuse, drug dependency or psychotic state).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01116895

Layout table for location information
Centre de Recherche Dermatologique du Quebec Metropolitain
Québec, Canada, G1V 4X7
Hôpital Saint-Louis, Service de Dermatologie
Paris, France
Sponsors and Collaborators
LEO Pharma
Layout table for investigator information
Principal Investigator: Yves Poulin, MD Centre de Recherche Dermatologique du Quebec Metropolitain

Layout table for additonal information
Responsible Party: LEO Pharma Identifier: NCT01116895     History of Changes
Other Study ID Numbers: LEO 22811-S22
First Posted: May 5, 2010    Key Record Dates
Results First Posted: October 3, 2018
Last Update Posted: December 20, 2018
Last Verified: December 2018
Keywords provided by LEO Pharma:
Psoriasis Vulgaris
Additional relevant MeSH terms:
Layout table for MeSH terms
Skin Diseases, Papulosquamous
Skin Diseases
Pharmaceutical Solutions